Fuda Cancer Hospital Treatments for International Patients
Fuda Cancer Hospital currently lists cryoablation, NanoKnife/irreversible electroporation (IRE), vascular intervention, embolization, brachytherapy, microwave ablation, PDT, HIPEC and CAR-T, among other therapies. The important question is not whether Fuda offers a technology — it is whether that technology is appropriate for your cancer type, stage, anatomy and prior treatment.
Quick answer: Fuda’s strongest international identity is minimally invasive and interventional
oncology, but its own department pages also describe surgery, chemotherapy, radiotherapy, targeted therapy and
multidisciplinary care. A minimally invasive option should be compared with the standard disease-specific treatment,
not chosen simply because it sounds newer or less invasive.
✓ Current Fuda treatment directory checked
✓ Standard care vs local techniques separated
✓ 2026 CAR-T update included
✓ No generic success-rate claims
Fuda Treatments at a Glance
| Treatment | What it is | Typical decision question | Parkmega evidence label |
|---|---|---|---|
| Cryoablation / CSA | Image-guided local tumor freezing. | Can a limited tumor be safely ablated, and is ablation preferable to surgery/radiation for this case? | Selected local treatment |
| NanoKnife / IRE | Non-thermal electrical ablation. | Is the tumor locally advanced or anatomically difficult, and does IRE add value after standard staging/systemic treatment? | Highly indication-specific |
| Vascular intervention | Catheter-based therapy delivered through tumor-feeding vessels. | Is locoregional arterial treatment appropriate for this organ and disease state? | Organ-specific |
| HepaSphere embolization | Drug-eluting microsphere embolization approach. | Does the patient have a tumor where transarterial embolization is evidence-based and technically feasible? | Selected locoregional use |
| Brachytherapy | Radiation source placed inside or near a tumor. | Would internal radiation improve local control compared with or alongside other radiation/surgery options? | Disease-specific radiation |
| Microwave ablation | Thermal tumor ablation using microwave energy. | Is the lesion small/local enough for thermal ablation, and how close is it to critical structures? | Selected solid tumors |
| HIPEC | Heated chemotherapy delivered into the abdominal cavity. | Is there a peritoneal-surface malignancy where cytoreductive surgery + HIPEC is appropriate at an experienced center? | Very indication-specific |
| CAR-T | Engineered autologous T-cell therapy. | Does the exact blood-cancer subtype and treatment history match a licensed cellular-therapy indication? | 2026 Fuda pathway published |
Fuda’s live therapy directory checked September 2026.
Jump to a Fuda Treatment
Cryoablation
Freezing selected tumor tissue under image guidance.
Read →NanoKnife / IRE
Electrical ablation for selected anatomically difficult tumors.
Read →Vascular Intervention
Catheter-based locoregional treatment and embolization.
Read →CAR-T
2026 Fuda pathway for selected adult large B-cell lymphoma.
Read →
Cryosurgical Ablation · CSA
Listed by Fuda
Cryoablation at Fuda Cancer Hospital
Cryoablation destroys selected tumor tissue through controlled cycles of freezing and thawing. Fuda has promoted cryosurgical ablation for many years and continues to list it among its signature therapies. The hospital’s older cryosurgery page also reports a large historical procedural experience; Parkmega treats those volume and superiority statements as hospital-published claims, not independent evidence of better outcomes.
When a cryo review may make sense
- There is a defined local tumor target on CT/MRI
- The lesion is technically reachable by image-guided probes
- Surgery is not possible, not preferred or needs a less-invasive alternative
- Local control is clinically meaningful
- The treating team can explain how systemic disease will also be managed
What must be checked first
- Organ and tumor-specific standard of care
- Size, number and location of lesions
- Distance from bowel, vessels, nerves or other critical structures
- Whether disease is local or widely metastatic
- Whether one or several sessions are expected
Key point: “minimally invasive” is a procedural description, not an efficacy ranking. A technically
possible cryoablation can still be the wrong first treatment if curative surgery, definitive radiation or systemic
therapy is more appropriate for that cancer.
Irreversible Electroporation
Listed by Fuda
NanoKnife / IRE at Fuda
Irreversible electroporation uses short high-voltage electrical pulses to create permanent pores in cell membranes. It is commonly called NanoKnife. Unlike microwave or radiofrequency ablation, it is described as non-thermal, which is one reason it is considered for selected tumors near important structures.
Fuda has listed IRE since 2015 and its current pages associate the technique with pancreatic, liver, renal, prostate, gallbladder and bile-duct tumors. Those hospital indication lists are broad; they should not be read as proof that IRE is standard treatment for every tumor in those organs.
Independent pancreatic-cancer context: a 2024 expert consensus on pancreatic IRE recommended
considering it in selected stage III pancreatic cancer and inoperable recurrent disease after previous local
treatment, while also defining important contraindications and technical requirements. A 2025 surgical review
likewise discusses IRE as an option in borderline-resectable and locally advanced pancreatic cancer. That is a
much narrower clinical question than “Can NanoKnife treat pancreatic cancer?”
Records needed for an IRE opinion
- High-quality contrast CT and/or MRI
- Exact tumor dimensions
- Relationship to major vessels and ducts
- Metastatic staging
- Prior chemotherapy/radiation response
- Performance status and major cardiac history
Questions to ask Fuda
- Why IRE instead of surgery or radiation?
- Is the goal margin accentuation, local control or palliation?
- How many electrodes are expected?
- What systemic therapy is planned before/after?
- What complication risks are specific to this anatomy?
- What imaging defines treatment response?
See also: Pancreatic Cancer Treatment in China.
Cancer Vascular Intervention · Embolization
Listed by Fuda
Vascular Interventional Therapy at Fuda
Vascular interventional oncology uses catheters to reach vessels supplying a tumor and deliver treatment locally and/or reduce tumor blood flow. Fuda’s current therapy directory lists Cancer Vascular Intervention and a separate HepaSphere drug-eluting microsphere embolization approach.
What changes the indication
- Primary organ and tumor histology
- Arterial blood supply
- Liver/kidney and overall organ function
- Extent of extra-organ metastatic disease
- Prior embolization, surgery or radiation
- Whether treatment is combined with systemic therapy
What to ask before treatment
- Exact catheter procedure name
- Drug and/or embolic material
- Number of expected sessions
- Imaging used to measure response
- Expected post-procedure syndrome and monitoring
- How this fits the full oncology plan
For liver tumors, compare local intervention with the broader pathway in Liver Cancer Treatment in China.
Internal radiation
Listed by Fuda
Brachytherapy / Iodine-125 Seed Implantation
Brachytherapy places radioactive sources directly inside or near selected tumor tissue so radiation is concentrated locally. Fuda’s treatment page describes iodine-125 seed implantation and lists a wide range of possible cancer sites.
Do not interpret a long indication list as universal suitability. Brachytherapy has established
roles in some cancers and much more selective roles in others. A radiation oncologist should explain why implanted
sources are preferred to external-beam radiation, surgery, systemic treatment or observation for the exact disease.
Ask about radiation planning
- Is brachytherapy definitive, boost or salvage treatment?
- Which isotope and dose are planned?
- What organs at risk are nearby?
- Is prior radiation relevant?
- What imaging confirms seed placement?
For prostate cancer
Seed brachytherapy can be an established prostate-radiation option in appropriate risk groups, but patient selection depends on disease risk, prostate anatomy and competing radiation/surgical options.
Thermal ablation
Fuda page updated 2024
Microwave Ablation at Fuda
Fuda’s current microwave-ablation page describes placement of an ablation needle under ultrasound or CT guidance and heating tumor tissue with microwave energy. This is a local treatment, not systemic cancer therapy.
Potential strengths of a local-ablation approach
- Targets a defined lesion rather than the whole body
- May avoid major open surgery in selected cases
- Can be image guided
- Can be combined with other cancer treatment
Limits
- Does not automatically treat microscopic/systemic disease
- Lesion size and location affect feasibility
- Nearby structures can constrain the ablation margin
- Recurrence elsewhere still requires a systemic plan
Other Therapies Listed by Fuda
HIPEC
Hyperthermic intraperitoneal chemotherapy delivers heated chemotherapy into the abdominal cavity. Its role is highly disease-specific and often linked to major cytoreductive surgery rather than being a standalone “wash.”
Photodynamic Therapy
Fuda lists PDT in its treatment directory. Appropriateness depends on tumor location, photosensitizer, light access and whether a recognized disease-specific indication exists.
Revolve Resection
Fuda lists a revolve/vacuum-assisted resection technique. The exact indication should be verified from the specific department and pathology rather than inferred from the device name.
Fuda’s website contains other older individualized-treatment concepts and therapy names. Parkmega
does not automatically reproduce every historical modality as a current evidence-based treatment. Before publishing
or recommending an older technique, we verify that Fuda currently offers it and that it is medically relevant to the
diagnosis.
Major 2026 update
Published August 14, 2026
CAR-T Therapy at Fuda
Fuda’s official website now has a current CAR-T page. It describes remote pre-treatment evaluation and discusses Yescarta (axicabtagene ciloleucel) for selected adult patients with large B-cell lymphoma. This materially changes the way Fuda should be described compared with older Parkmega content.
What this does not mean: it does not establish that Fuda provides CAR-T for every lymphoma,
leukemia or solid tumor. CAR-T eligibility is product- and indication-specific and requires pathology, previous
lines of therapy, imaging, organ-function assessment and a cellular-therapy safety plan.
Records for a CAR-T review
- Exact lymphoma subtype
- Pathology and immunophenotype
- MYC/BCL2/BCL6 or other relevant molecular tests
- All previous treatment lines and responses
- Latest PET-CT / CT / MRI
- Current blood counts and organ function
- Major infection / cardiovascular history
Questions for Fuda before travel
- Which exact product is proposed?
- Does the patient meet the licensed/current indication?
- Where are cells collected and manufactured?
- What is the expected manufacturing timeline?
- How are CRS and neurologic toxicity managed?
- What bridging therapy is planned if needed?
- What is the complete hospitalization plan?
See the broader guide: CAR-T Therapy in China.
Does Fuda Only Do Minimally Invasive Treatment?
No. Fuda’s current department directory describes Medical Oncology, Surgical Oncology, thoracic,
abdominal, hepatobiliary/GI, breast, gynecologic and other departments. Its own Medical Oncology description says
care is based on standardized cancer treatment while being characterized by minimally invasive approaches.
Surgical Oncology
Fuda lists multiple surgical departments and disease-specific operations. A patient should compare standard curative surgery with any proposed ablation when both are technically possible.
Medical Oncology
Chemotherapy, targeted therapy, immunotherapy and disease-specific systemic strategies remain essential when cancer is systemic or at high risk of microscopic spread.
Radiotherapy / Brachytherapy
Local ablation and radiation solve different problems. Ask whether radiation is potentially definitive before choosing a percutaneous procedure mainly because it is less invasive.
Which Fuda Treatment Might Be Discussed by Cancer Type?
The table below is a routing guide, not a treatment recommendation. It shows the kinds of questions worth asking after standard staging.
| Cancer | Possible Fuda-specific question | What must come first | Parkmega guide |
|---|---|---|---|
| Pancreatic | IRE/NanoKnife in selected locally advanced or anatomically difficult disease. | Resectability, metastatic staging, systemic therapy history and vessel anatomy. | Pancreatic cancer → |
| Liver | Vascular intervention, embolization, microwave/cryo ablation or IRE in selected lesions. | Liver function, tumor number/size, vascular invasion, extrahepatic disease and standard HCC pathway. | Liver cancer → |
| Lung | Local ablation for selected lesions or intervention in a multidisciplinary plan. | Histology, molecular markers, operability, radiation options and systemic staging. | Lung cancer → |
| Prostate | Brachytherapy or selected local techniques. | Risk group, PSA, MRI, biopsy grade, metastatic work-up and comparison with surgery/external-beam radiation. | Prostate cancer → |
| Breast | Fuda consultation may include surgery and selected local/interventional procedures. | ER/PR/HER2 status, stage and standard breast-oncology treatment. | Breast cancer → |
| Large B-cell lymphoma | CAR-T eligibility review for selected adults under Fuda’s 2026 pathway. | Exact subtype, prior lines, PET response and licensed-product indication. | CAR-T in China → |
When Fuda May Be Worth a Treatment Review
The case contains a specific local-treatment question
- Standard staging is already available
- There is a defined tumor target on imaging
- A major surgery is not possible or needs comparison with a less-invasive approach
- The oncologist wants another local-control option
- The patient has recurrent/local disease requiring salvage review
- Fuda proposes a named technique with a clear medical goal
The main issue is not an interventional procedure
- Potentially curative standard surgery has not been evaluated
- Modern systemic therapy depends on biomarkers not yet tested
- A major academic disease-specific program is more relevant
- The proposed procedure treats only one lesion while disease is widespread
- The hospital proposal does not state the treatment goal
- The recommendation relies mostly on testimonials or “new technology” language
Questions to Ask About Any Fuda Treatment Proposal
1. What exact problem is this treatment solving?
Curative treatment, local control, symptom relief, bridge therapy or palliation should be stated clearly.
2. Why this method instead of the standard option?
Ask for a direct comparison with surgery, radiation and systemic therapy for the same diagnosis and stage.
3. What evidence applies to this exact cancer?
Evidence from one tumor type should not be transferred automatically to another organ or disease stage.
4. Who will perform the procedure?
Request the doctor, department and recent experience with the same tumor/anatomy.
5. How will success be measured?
Define follow-up CT/MRI/PET timing and what counts as local control or treatment failure.
6. What happens if it does not work?
Know the next-line plan before committing to a procedure that could delay another treatment.
What Records Should You Send for a Fuda Treatment Review?
Core oncology file
- Pathology report and immunohistochemistry
- Current stage
- CT / MRI / PET-CT reports
- DICOM imaging if available
- Prior surgery
- Radiation history
- Chemotherapy / targeted / immunotherapy history
For treatment selection
- Relevant molecular and biomarker results
- Current symptoms and performance status
- Major heart/lung/kidney/liver conditions
- Prior local ablation or embolization
- Latest treating-oncologist recommendation
- Any Fuda proposal already received
- Any competing China hospital opinion
How Parkmega Reviews a Fuda Treatment Case
Classify the disease
Diagnosis, histology, stage, biomarkers and prior treatment establish the treatment problem.
Identify the Fuda-specific question
Cryo, IRE, intervention, brachytherapy, surgery, systemic treatment or CAR-T eligibility.
Compare alternatives
We check whether another Chinese disease-specific center should review the same file before a decision.
Request plan + cost
Only after the medical method is defined do we move to admission, expected stay and written cost estimate.
Do Not Choose the Technology Before the Diagnosis Chooses the Treatment
Send the pathology, staging and recent imaging. We’ll help identify whether the case is really a cryo, NanoKnife, intervention, brachytherapy, CAR-T or standard oncology question — and whether Fuda should be compared with another Chinese center before travel.
✓ Treatment fit before travel
✓ Compare standard care when needed
✓ Cost requested after method is defined
Related Fuda and China Cancer Guides
Frequently Asked Questions
Direct answers to common questions about treatments offered by Guangzhou Fuda Cancer Hospital.
What treatments does Fuda Cancer Hospital offer?
Fuda’s current therapy directory lists CAR-T, NanoKnife/irreversible electroporation, cryosurgical ablation, cancer vascular intervention, HepaSphere embolization, brachytherapy, microwave ablation, photodynamic therapy, HIPEC and other therapies. Its department pages also describe surgery, chemotherapy, radiotherapy, targeted therapy and multidisciplinary oncology.
What is Fuda Cancer Hospital best known for?
Internationally, Fuda is especially associated with minimally invasive and interventional oncology, including cryoablation and NanoKnife/IRE. That does not make those methods the best treatment for every cancer. The diagnosis, stage, anatomy and standard disease-specific options should determine whether a Fuda technique deserves review.
Does Fuda offer NanoKnife treatment?
Yes. Fuda currently lists irreversible electroporation, commonly called NanoKnife, among its therapies. IRE is a non-thermal local-ablation technique and is highly indication-specific. For pancreatic cancer, modern expert guidance discusses IRE mainly in selected locally advanced or recurrent settings rather than as a universal alternative to standard treatment.
Does Fuda offer cryoablation?
Yes. Cryosurgical ablation has been a long-standing Fuda treatment and remains in the hospital’s current therapy directory. Whether cryoablation is appropriate depends on the tumor organ, size, number, location, metastatic status and whether surgery, radiation or systemic therapy is a better option.
Does Fuda Cancer Hospital offer CAR-T therapy?
Fuda published a current CAR-T page on August 14, 2026. It describes remote evaluation and a Yescarta (axicabtagene ciloleucel) pathway for selected adult large B-cell lymphoma patients. This should not be extrapolated to every leukemia, lymphoma or solid tumor; current eligibility and product access must be verified for the individual patient.
Does Fuda only use minimally invasive cancer treatments?
No. Fuda’s department directory describes Medical Oncology, Surgical Oncology and disease-specific surgical departments as well as radiotherapy, chemotherapy, targeted therapy and minimally invasive treatments. Its distinctive international marketing emphasizes local and interventional techniques, but those are not the hospital’s only forms of cancer care.
Which cancers can be treated with Fuda NanoKnife or cryoablation?
Fuda lists multiple solid-tumor sites for local ablation, including pancreatic, liver, renal, prostate and other cancers. A hospital indication list is not enough to determine candidacy. The exact tumor anatomy, number of lesions, metastatic status and standard treatment options must be reviewed first.
Is minimally invasive treatment better than surgery?
Not automatically. “Minimally invasive” describes how a procedure is performed, not whether it provides better cancer control. For some patients a local ablation is valuable; for others standard surgery, radiation or systemic treatment offers the stronger disease-specific evidence. The methods should be compared for the same diagnosis and stage.
How much do Fuda treatments cost?
Fuda does not have one universal price for cryoablation, NanoKnife, surgery, intervention or other cancer treatment. The bill depends on the treatment plan, procedure complexity, materials, drugs, anesthesia, imaging and hospital stay. See Parkmega’s separate Fuda Cancer Hospital Cost guide and request a written case-specific estimate.
What should I send for a Fuda treatment review?
Send pathology, stage, recent CT/MRI/PET-CT, DICOM images if possible, prior surgery/radiation/systemic treatment, relevant biomarkers, major medical conditions and any Fuda proposal already received. The purpose is to identify which treatment question should actually be sent to Fuda.
Sources and Evidence Labels
- Fuda — current Therapies directory. Current hospital directory listing CAR-T, IRE/NanoKnife, cryosurgical ablation, cancer vascular intervention, HepaSphere embolization, brachytherapy, microwave ablation, revolve resection and other therapies. Fuda Therapies.
- Fuda — current Cancer Treatment page. Lists therapies, individualized treatment and cancer categories, including PDT and HIPEC. Fuda Cancer Treatment.
- Fuda — Department directory. Describes Medical Oncology, Surgical Oncology and organ-specific departments and states that standardized cancer treatment is combined with minimally invasive approaches such as IRE, cryoablation and cancer intervention. Fuda Departments.
- Fuda — CAR-T Therapy, August 14, 2026. Current page describing remote pre-treatment evaluation and Yescarta/axicabtagene ciloleucel for selected adult large B-cell lymphoma. Fuda CAR-T Therapy.
- Fuda — Cryosurgical Ablation. Long-standing hospital page describing its cryoablation program and historical experience. Parkmega treats hospital-reported procedure volumes and superiority claims as self-published rather than independent comparative evidence. Fuda Cryosurgical Ablation.
- Fuda — Microwave Ablation, updated 2024. Describes CT/ultrasound-guided thermal ablation using microwave energy. Fuda Microwave Ablation.
- Fuda — Brachytherapy. Hospital page describing iodine-125 seed implantation and a broad hospital-published indication list. Fuda Brachytherapy.
- Pancreatic IRE expert consensus, 2024. Modified Delphi consensus provides patient-selection, contraindication, technical and follow-up recommendations for pancreatic irreversible electroporation; it discusses selected stage III and inoperable recurrent disease. PubMed PMID 38993594.
- Role of IRE for pancreatic cancer, 2025. Surgical review discussing IRE in borderline-resectable and locally advanced pancreatic cancer. PubMed PMID 40769705.
Evidence rule: Fuda’s website is used to establish what the hospital currently lists or describes. It is not treated as independent evidence that a Fuda therapy is superior. Where a treatment is particularly indication-sensitive, independent medical literature is used to narrow the interpretation.
Medical note: This page is for medical-travel research and hospital matching. It does not determine candidacy, replace an oncology consultation or guarantee treatment availability or outcome.
Get a Case-Specific Treatment Opinion Before You Travel
Send the pathology, stage and current scans. We’ll identify whether the useful question for Fuda is cryoablation, NanoKnife/IRE, vascular intervention, brachytherapy, surgery, systemic treatment or CAR-T — and whether another China center should review the same case.